| HOME >> BIOLOGY >> TECHNOLOGY |
BETHESDA, Md., March 19, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that Linda F. Powers , the Company's Chairman and Chief Executive Officer, will be presenting at the 25th Annual ROTH Conference at 8:30 a.m. PDT on Wednesday, March 20, 2013, at the Ritz-Carlton, Laguna Niguel, Dana Point, California.
(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)
Ms. Powers' presentation will discuss the Company's lead Phase III trial with DCVax-L for brain cancer, including guidance on enrollment, progress in Europe, and anticipated timelines for major milestones. Ms. Powers will also discuss the Company's pending Phase I/II trial with DCVax-Direct for all solid tumor cancers that are inoperable, which is preparing to launch in Q2. Ms. Powers will comment on the Company's key strengths and differentiation in the immune therapy space, and will announce certain new developments.
The presentation will take place in Track 8 of the conference, in The Promenade – White Room, and will be available by web cast at http://wsw.com/webcast/roth27/nwbo/. The webcast will remain available for 90 days following the presentation. It will also be available on the NW Bio Website starting on Thursday, March 21, 2013, at www.nwbio.com.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more e
'/>"/>
| SOURCE Northwest Biotherapeutics Copyright©2012 PR Newswire. All rights reserved |